CA2276276A1 - Cancer treatment drug - Google Patents
Cancer treatment drug Download PDFInfo
- Publication number
- CA2276276A1 CA2276276A1 CA002276276A CA2276276A CA2276276A1 CA 2276276 A1 CA2276276 A1 CA 2276276A1 CA 002276276 A CA002276276 A CA 002276276A CA 2276276 A CA2276276 A CA 2276276A CA 2276276 A1 CA2276276 A1 CA 2276276A1
- Authority
- CA
- Canada
- Prior art keywords
- drug
- cancer
- kotshyi
- boss
- cancer treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 229940079593 drug Drugs 0.000 title claims abstract description 23
- 201000011510 cancer Diseases 0.000 title claims abstract description 21
- 238000011282 treatment Methods 0.000 title abstract description 4
- 240000005523 Peganum harmala Species 0.000 claims abstract description 6
- 239000000284 extract Substances 0.000 claims abstract description 5
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 4
- 241001529849 Dracocephalum Species 0.000 claims description 5
- 235000005126 Peganum harmala Nutrition 0.000 claims description 4
- 238000011275 oncology therapy Methods 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003157 cancerolytic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 3
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000035773 mitosis phase Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a cancer treatment drug containing two biological plant active ingredients having a cytotoxic action and carcinolytic properties, namely extracts from the plants Peganum Harmala L. and Drakocephalum Kotshyi Boss.
Description
., . CA 02276276 1999-06-28 PHARMACEUTICAL RESEARCH CENTER
Drug for cancer therapy The invention concerns a drug for cancer therapy, which is founded on a biological basis.
Cancer is an illness in which body cells grow uncontrolledly. Various therapies are known for preventing or at least confining cell growth of that kind. One of the therapies which is most frequently applied at the present time is so-called chemotherapy which suffers from serious side effects without however resulting in sustained successes.
Tests with biological cancer therapies alone have also hitherto not afforded long-lasting successes because it was also hitherto not possible for the cancer cells which are formed in the human body to be effectively destroyed with those therapies.
The object of the present invention is to provide a drug or pharmaceutical preparation which has anti-cancer or cytostatic effects) by means of which cancer cells can be effectively destroyed or at least curbed.
In accordance with the invention that object is attained by a drug having the features of claim 1.
Advantageous configurations and embodiments of the invention are the subject-matter of the appendant claims.
The anti-cancer agent according to the invention is a drug which contains two vegetable substances with cytotoxic action and which can be administered orally and/or rectally and/or parenterally.
This combination anti-cancer preparation preferably contains extracts of two plants, more specifically Peganum harmala L. and Dracocephalum Kotshyi Boss which contain substances having a cancer-inhibiting action.
Plants of that kind are indigenous to Iran.
Phytochemical investigations of those plants confirm inter alia the presence of active substance such as alkaloids, flavonoids, tannin, saponins, steroids, proteins, lipids, carbohydrates, essential oils.
minerals, amino acids and so forth.
The constituents or ingredients of the plant extracts to be used in accordance with the invention are firstly prepared in the form of alcoholic and aqueous extracts or solutions. Granules are produced from the mixture which is formed therefrom. The granules and extracts which are obtained in that way are processed to form tablets or other medicinal forms of presentation in order to administer them to patients.
The drug according to the invention has inter alia cytotoxic, anti phlogistic, anti-inflammatory, analgesic, anti-bacterial and anti-viral actions.
The biological anti-cancer agent according to the invention acts as a mitosis inhibitor and intervenes with an inhibiting effect in the mitosis phase in cell division of cancer-affected cells.
The biological anti-cancer agent according to the invention combines after administration with the deoxyribonucleic acid (DNA) chain and thereby prevents the formation of ribonucleic acid (RNA). In that way it interferes with the amino acids of the cells which are affected by cancer and thus prevents cancer cell growth.
The molecular building structure of the biological anti-cancer agent or preparati on accordi ng to the i nventi on i s such that the agent functi ons as a physiological and body-compatible agent in the body.
It has been found that the drug or preparation according to the invention gives rise to positive therapy effects in relation to various cancer tumours, for example mammary carcinoma, carcinomas of the gastro intestinal tract, brain tumours and the like.
A particular advantage of the invention is that the positive therapy effect can be achieved in relation to cancer cells, without side effects of any consequence.
In particular the drug or preparation according to the invention, upon administration, does rot have any adverse side effects on the blood count and the natural blood components.
Drug for cancer therapy The invention concerns a drug for cancer therapy, which is founded on a biological basis.
Cancer is an illness in which body cells grow uncontrolledly. Various therapies are known for preventing or at least confining cell growth of that kind. One of the therapies which is most frequently applied at the present time is so-called chemotherapy which suffers from serious side effects without however resulting in sustained successes.
Tests with biological cancer therapies alone have also hitherto not afforded long-lasting successes because it was also hitherto not possible for the cancer cells which are formed in the human body to be effectively destroyed with those therapies.
The object of the present invention is to provide a drug or pharmaceutical preparation which has anti-cancer or cytostatic effects) by means of which cancer cells can be effectively destroyed or at least curbed.
In accordance with the invention that object is attained by a drug having the features of claim 1.
Advantageous configurations and embodiments of the invention are the subject-matter of the appendant claims.
The anti-cancer agent according to the invention is a drug which contains two vegetable substances with cytotoxic action and which can be administered orally and/or rectally and/or parenterally.
This combination anti-cancer preparation preferably contains extracts of two plants, more specifically Peganum harmala L. and Dracocephalum Kotshyi Boss which contain substances having a cancer-inhibiting action.
Plants of that kind are indigenous to Iran.
Phytochemical investigations of those plants confirm inter alia the presence of active substance such as alkaloids, flavonoids, tannin, saponins, steroids, proteins, lipids, carbohydrates, essential oils.
minerals, amino acids and so forth.
The constituents or ingredients of the plant extracts to be used in accordance with the invention are firstly prepared in the form of alcoholic and aqueous extracts or solutions. Granules are produced from the mixture which is formed therefrom. The granules and extracts which are obtained in that way are processed to form tablets or other medicinal forms of presentation in order to administer them to patients.
The drug according to the invention has inter alia cytotoxic, anti phlogistic, anti-inflammatory, analgesic, anti-bacterial and anti-viral actions.
The biological anti-cancer agent according to the invention acts as a mitosis inhibitor and intervenes with an inhibiting effect in the mitosis phase in cell division of cancer-affected cells.
The biological anti-cancer agent according to the invention combines after administration with the deoxyribonucleic acid (DNA) chain and thereby prevents the formation of ribonucleic acid (RNA). In that way it interferes with the amino acids of the cells which are affected by cancer and thus prevents cancer cell growth.
The molecular building structure of the biological anti-cancer agent or preparati on accordi ng to the i nventi on i s such that the agent functi ons as a physiological and body-compatible agent in the body.
It has been found that the drug or preparation according to the invention gives rise to positive therapy effects in relation to various cancer tumours, for example mammary carcinoma, carcinomas of the gastro intestinal tract, brain tumours and the like.
A particular advantage of the invention is that the positive therapy effect can be achieved in relation to cancer cells, without side effects of any consequence.
In particular the drug or preparation according to the invention, upon administration, does rot have any adverse side effects on the blood count and the natural blood components.
2 The drug or preparation according to the invention can be administered as a mono- and/or combination therapy preparation with other biosubstances and anti-tumour agents which have been produced on a biological and/or conventional basis.
The drug or preparation according to the invention has a synergistic effect in combination with oral oxygen therapy, whereby the effect of the anti-cancer action is increased.
It has been found that the agent or preparation according to the invention has a relaxant and relief effect. in particular in regard to smooth musculatures.
The drug or preparation according to the invention has immunostimulating and immunomodulating actions. Those properties have been investigated and confirmed in relation to animals whose immune systems were crippled by dimethylbenzanthracene (DMBA) as a carcinogenic and immunosuppressive agent. In those animals, after treatment with the biological anti-cancer agent according to the invention, immunostimulation and immunomodulation were noted and documented. Those positive effects on the immune system of a human being have also been demonstrated.
It was also possible to demonstrate a reduction in tumour markers in the case of cancer patients treated with the drug or preparation according to the invention.
Pharmacodynamical investigations with the drug or preparation according to the invention showed a lethal dose (LDso) of 657.5 mg/kg bodyweight in the case of investigated mice.
Pharmacodynamical comparative investigations with other anti-tumour agents such as Vincristin. Vinblastin and Chlorambucil showed that the drug or preparation according to the invention has optimum compatibility while the previously known cancer-treatment agents give rise to serious side effects which did not occur when using the drug according to the invention.
The cancer-inhibiting action of the drug or preparation according to the invention was confirmed and documented by various cell investigations and effects on cancer cells in humans and apes.
The drug or preparation according to the invention has a synergistic effect in combination with oral oxygen therapy, whereby the effect of the anti-cancer action is increased.
It has been found that the agent or preparation according to the invention has a relaxant and relief effect. in particular in regard to smooth musculatures.
The drug or preparation according to the invention has immunostimulating and immunomodulating actions. Those properties have been investigated and confirmed in relation to animals whose immune systems were crippled by dimethylbenzanthracene (DMBA) as a carcinogenic and immunosuppressive agent. In those animals, after treatment with the biological anti-cancer agent according to the invention, immunostimulation and immunomodulation were noted and documented. Those positive effects on the immune system of a human being have also been demonstrated.
It was also possible to demonstrate a reduction in tumour markers in the case of cancer patients treated with the drug or preparation according to the invention.
Pharmacodynamical investigations with the drug or preparation according to the invention showed a lethal dose (LDso) of 657.5 mg/kg bodyweight in the case of investigated mice.
Pharmacodynamical comparative investigations with other anti-tumour agents such as Vincristin. Vinblastin and Chlorambucil showed that the drug or preparation according to the invention has optimum compatibility while the previously known cancer-treatment agents give rise to serious side effects which did not occur when using the drug according to the invention.
The cancer-inhibiting action of the drug or preparation according to the invention was confirmed and documented by various cell investigations and effects on cancer cells in humans and apes.
3 The extract obtained and produced in accordance with the invention from two specific plants and its fractions were allowed to act on cancer cells and control cells. The progression of that effect was monitored through an electron microscope. Ultra-structural damage to the cancer cells was found. in comparison with healthy control cells.
In cl i ni cal studi es , when usi ng the agent accordi ng to the i nventi on i n rel ati on to cancer pati ents , there was found i n part total remi ssi on as well as an increase in life expectancy and an improvement in quality of life.
The invention is further described hereinafter by reference to a practical embodiment of a cancer-inhibiting drug set out in table form.
Constituent mg/tablet Peganum harmala L. 142.7 23.8 Dracocephalum K.B. 19.6 3.3 Sugar powder 15,7 2.6 Calcium carbonate 43.6 7.3 Polyvinyl pyrrolidone (PVP)12.5 2.0 Starch 166.5 27.g Lactose 156.0 26.0 Carboxymethylcellulose (CMC)10.0 1.6 Microcrystalline cellulose 24.0 4.0 (MCC>
Aerosyl 9.4 1.6 600.0 mg 100.0 _ 4
In cl i ni cal studi es , when usi ng the agent accordi ng to the i nventi on i n rel ati on to cancer pati ents , there was found i n part total remi ssi on as well as an increase in life expectancy and an improvement in quality of life.
The invention is further described hereinafter by reference to a practical embodiment of a cancer-inhibiting drug set out in table form.
Constituent mg/tablet Peganum harmala L. 142.7 23.8 Dracocephalum K.B. 19.6 3.3 Sugar powder 15,7 2.6 Calcium carbonate 43.6 7.3 Polyvinyl pyrrolidone (PVP)12.5 2.0 Starch 166.5 27.g Lactose 156.0 26.0 Carboxymethylcellulose (CMC)10.0 1.6 Microcrystalline cellulose 24.0 4.0 (MCC>
Aerosyl 9.4 1.6 600.0 mg 100.0 _ 4
Claims (4)
1. A drug for cancer therapy characterised in that it contains two biological vegetable active substances with cytotoxic action which thus have cancer cell-destroying properties.
2. A drug as set forth in claim 1 characterised in that as active substances having cancer cell-destroying properties it contains extracts from the plants Peganum Harmala L. and Dracocephalum Kotshyi Boss.
3. A drug as set forth in claim 1 or claim 2 characterised in that it contains about 24% Peganum Harmala L. and between about 3 and 4%
Dracocephalum Kotshyi Boss, with the balance fillers.
Dracocephalum Kotshyi Boss, with the balance fillers.
4. A drug as set forth in claim 3 characterised in that it contains 23.8% Peganum Harmala L. and 3.3% Dracocephalum Kotshyi Boss.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP1997/006155 WO1999024048A1 (en) | 1997-11-06 | 1997-11-06 | Cancer treatment drug |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2276276A1 true CA2276276A1 (en) | 1999-05-20 |
Family
ID=8166782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002276276A Abandoned CA2276276A1 (en) | 1997-11-06 | 1997-11-06 | Cancer treatment drug |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0951291A1 (en) |
JP (1) | JP2001514671A (en) |
CA (1) | CA2276276A1 (en) |
WO (1) | WO1999024048A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
RU2609018C2 (en) * | 2010-08-24 | 2017-01-30 | Джи Ти Икс, ИНК. | Compounds for treating cancer |
CN102286085B (en) * | 2011-07-25 | 2014-06-11 | 新疆大学 | Peganum harmala lipid transfer protein and preparation method and use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1034135A (en) * | 1987-10-27 | 1989-07-26 | 新疆医学院第二附属医院 | The preparation method of peganum harmala seed extract |
CN1047528C (en) * | 1993-11-18 | 1999-12-22 | 王世渝 | Pharmaceutics of common peganum herb and its preparation |
-
1997
- 1997-11-06 WO PCT/EP1997/006155 patent/WO1999024048A1/en not_active Application Discontinuation
- 1997-11-06 EP EP97948892A patent/EP0951291A1/en not_active Withdrawn
- 1997-11-06 JP JP52524399A patent/JP2001514671A/en active Pending
- 1997-11-06 CA CA002276276A patent/CA2276276A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2001514671A (en) | 2001-09-11 |
EP0951291A1 (en) | 1999-10-27 |
WO1999024048A1 (en) | 1999-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ijaz et al. | Nigella sativa (Prophetic Medicine): A Review. | |
Ghosh | Tannins from foods to combat diseases | |
Namba | Maitake D-fraction: healing and preventive potential for cancer | |
US6395311B2 (en) | Multicomponent biological vehicle | |
US20190008907A1 (en) | Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases | |
JPH0344048B2 (en) | ||
US20090142419A1 (en) | Anti-inflammatory extract and agent and method for the production thereof | |
Chekka et al. | Momordica charantia: A natural medicinal plant | |
CA2700338C (en) | Anti-aids, anti-tumor, immune system stimulating herbal composition and production method | |
CA2276276A1 (en) | Cancer treatment drug | |
KR20030055154A (en) | A composition for treating a dermatitis and a method of preparing the same | |
US11357813B2 (en) | Composition comprising tannins | |
Rimple et al. | Poly pharmacological effects of green blood therapy: An update | |
CN113209065B (en) | Use of alkaloid compounds for the production of products for the prevention and/or treatment of heart damage | |
RU2408383C1 (en) | Composition with antineoplastic and adaptogenic activity (versions) and based drug (versions) | |
CN109731019B (en) | A composition with chemotherapy synergistic effect comprises components, preparation and application | |
US20050182037A1 (en) | Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof | |
CN102008470B (en) | Compound preparation and use thereof for preventing and treating noise induced hearing damage | |
KR102028383B1 (en) | Composition for preventing or treating hearing loss | |
CN111728985B (en) | A composition containing oviductus Ranae as main ingredient and its application | |
KR102007096B1 (en) | Composition for preventing or treating hearing loss comprising Viscum ovalifolium extracts | |
JPH06199696A (en) | Carcinostatic anticancer agent | |
CN105343124A (en) | Flesh-engendering and skin-growing medicinal powder | |
BESBES et al. | Study of the cytotoxicity and therapeutic virtues of some aromatic and medicinal plants used in traditional Algerian medicine | |
WO2022264058A1 (en) | Composition for the prevention and/or treatment of inflammatory diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |